Clinical Trial Update: Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing the prevention of postoperative pulmonary complications after reversal with sugammadex or neostigmine has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Complications Following Surgery

Drugs mentioned

• Neostigmine (neostigmine)
• Sugammadex (sugammadex)

Snippet

Sponsor: Northern Sydney Anaesthesia Research Institute | Conditions: Pulmonary Complications | Phase 4 | Status: TERMINATED